文献速递糖尿病

2型糖尿病中肠促胰岛素效应丧失:系统综述与Meta分析

Loss of the Incretin Effect in Type 2 Diabetes: A Systematic Review and Meta-analysis.
PubMed 文献 · J Clin Endocrinol Metab · 2022-01-01

该系统综述与Meta分析检索PubMed、Scopus和Web-of-Science,纳入采用口服葡萄糖耐量试验(OGTT)与匹配血糖水平静脉葡萄糖输注的金标准方案测量肠促胰岛素效应(IE)的研究。结果显示,2型糖尿病(T2D)患者与糖耐量正常(NGT)者相比,IE加权均数差为-27.3%(CI -36.5%至-18.1%;P < .001;I2 = 86.6%),且受年龄影响(P < .005)。IE与糖耐量、BMI及空腹GIP独立相关;在T2D研究中,IE与OGTT葡萄糖剂量相关(P < .0001)。

要点

  • T2D患者IE较NGT者降低27.3%(加权均数差,CI -36.5%至-18.1%;P < .001;I2 = 86.6%)。
  • IE差异受年龄影响(P < .005)。
  • IE与糖耐量、BMI及空腹GIP独立相关(P < .05)。

核心结论

  • T2D患者较NGT者的IE损害一致但变异较大,年龄可能是影响IE差异的因素。
  • 糖耐量、BMI和空腹GIP与IE独立相关;仅在T2D受试者中,OGTT剂量是显著协变量。

研究设计与样本

  • 系统综述与Meta分析,检索PubMed、Scopus和Web-of-Science。
  • 纳入采用OGTT与匹配血糖水平静脉葡萄糖输注的金标准方案测量IE的研究。
  • 提取IE、性别、年龄、BMI、血红蛋白A1c、空腹值及血糖、胰岛素、C肽、葡萄糖依赖性促胰岛素多肽(GIP)和胰高血糖素样肽1(GLP-1)的曲线下面积(AUC);在T2D受试者中还记录T2D病程、诊断年龄和服用降糖药物受试者百分比。

主要发现

  • T2D受试者与NGT受试者之间IE加权均数差为-27.3%(CI -36.5%至-18.1%;P < .001;I2 = 86.6%),且受年龄影响(P < .005)。
  • 对NGT和T2D合并数据进行Meta回归,IE与糖耐量(T2D中IE较低)、BMI和空腹GIP呈负相关(P < .05)。
  • 仅对T2D研究进行Meta回归,IE与OGTT葡萄糖剂量相关(P < .0001)。
  • 基于胰岛素的IE大于基于C肽的IE(加权均数差11.2%,CI 9.2-13.2%;P < .0001;I2 = 28.1%);该IE差异与糖耐量和空腹血糖呈负相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 异质性I2 = 86.6%。
  • 异质性I2 = 28.1%。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Loss of the incretin effect (IE) in type 2 diabetes (T2D) contributes to hyperglycemia and the mechanisms underlying this impairment are unclear. OBJECTIVE: To quantify the IE impairment in T2D and to investigate the factors associated with it using a meta-analytic approach. METHODS: PubMed, Scopus, and Web-of-Science were searched. Studies measuring IE by the gold-standard protocol employing an oral glucose tolerance test (OGTT) and an intravenous glucose infusion at matched glucose levels were selected. We extracted IE, sex, age, body mass index (BMI), and hemoglobin A1c, fasting values, and area under curve (AUC) of glucose, insulin, C-peptide, glucose-dependent insulinotropic peptide (GIP) and glucagon-like peptide 1 (GLP-1). In subjects with T2D, we also recorded T2D duration, age at diagnosis, and the percentage of subjects taking antidiabetic medications. RESULTS: The IE weighted mean difference between subjects with T2D and those with normal glucose tolerance (NGT) was -27.3% (CI -36.5% to -18.1%; P < .001; I2 = 86.6%) and was affected by age (P < .005). By meta-regression of combined NGT and T2D data, IE was inversely associated with glucose tolerance (lower IE in T2D), BMI, and fasting GIP (P < .05). By meta-regression of T2D studies only, IE was associated with the OGTT glucose dose (P < .0001). IE from insulin was larger than IE from C-peptide (weighted mean difference 11.2%, CI 9.2-13.2%; P < .0001; I2 = 28.1%); the IE difference was inversely associated with glucose tolerance and fasting glucose. CONCLUSION: The IE impairment in T2D vs NGT is consistent though considerably variable, age being a possible factor affecting the IE difference. Glucose tolerance, BMI, and fasting GIP are independently associated with IE; in subjects with T2D only, the OGTT dose is a significant covariate.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Grespan E, Guolo A, Muscelli E, et al. Loss of the Incretin Effect in Type 2 Diabetes: A Systematic Review and Meta-analysis. J Clin Endocrinol Metab. 2022. PMID: 35397169. doi:10.1210/clinem/dgac213

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。